ANNX

$3.942.72%-0.11

Annexon Inc (ANNX)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$4.05

Offen:

$4.06

24-Stunden-Volumen:

2,276,778

Relatives Volumen:

0.64

Marktkapitalisierung:

$746.94M

Einnahmen:

Nettoeinkommen (Verlust:

-$196.48M

KGV:

EPS:

-$1.22

Netto-Cashflow:

-$183.16M

1W Leistung:

+4.79%

1M Leistung:

-5.97%

6M Leistung:

-31.48%

1Y Leistung:

+24.29%

1-Tages-Spanne:

$0.00$0.00

1-Wochen-Bereich:

$3.72$4.20

52-Wochen-Spanne:

$2.54$7.18

Annexon Inc Aktie (ANNX) Unternehmensprofil

Firmenname

Annexon Inc

Sektor

Healthcare

Branche

Biotechnology

Telefon

(650) 822-5500

Adresse

1400 SIERRA POINT PARKWAY, BRISBANE, USA

Mitarbeiter

Nächster Verdiensttermin

2026-11-09

Neueste SEC-Einreichungen

SEC

ANNX-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Annexon Inc Aktie (ANNX) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-08-13	Hochstufung	Citizens	Mkt Underperform → Mkt Perform
2026-07-21	Eingeleitet	Citizens	Mkt Underperform
2026-05-12	Eingeleitet	Goldman	Neutral
2025-12-23	Eingeleitet	Chardan Capital Markets	Buy
2024-03-01	Hochstufung	JP Morgan	Neutral → Overweight
2023-12-21	Hochstufung	BofA Securities	Neutral → Buy
2023-10-30	Eingeleitet	Wells Fargo	Overweight
2023-05-26	Herabstufung	BofA Securities	Buy → Neutral
2023-05-25	Herabstufung	JP Morgan	Overweight → Neutral
2022-09-16	Eingeleitet	Jefferies	Buy
2022-09-09	Eingeleitet	BTIG Research	Buy
2021-11-30	Eingeleitet	H.C. Wainwright	Buy
2021-09-23	Eingeleitet	Cantor Fitzgerald	Overweight
2021-01-26	Eingeleitet	Needham	Buy
2020-08-18	Eingeleitet	BofA Securities	Buy
2020-08-18	Eingeleitet	Cowen	Outperform
2020-08-18	Eingeleitet	JP Morgan	Overweight

Finanzdaten der Annexon Inc-Aktie (ANNX)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	-	-	0.00	0.00	0.00
Research and development USD (M)	184.70	119.45	113.76	112.50	100.07
Operating expenses USD (M)	216.41	154.07	143.72	145.60	130.71
Operating income USD (M)	-216.41	-154.07	-143.72	-145.60	-130.71
Income before tax USD (M)	-206.69	138.20	134.24	141.95	-130.32
Income tax expense USD (M)	0.00	0.00	0.00	-	-
Net income USD (M)	-206.69	-138.20	-134.24	-141.95	-130.32
Basic EPS USD/shares	-1.34	-1.01	-1.77	-2.60	-
Diluted EPS USD/shares	-1.34	-1.01	-1.77	-2.60	-
Basic weighted shares shares (M)	155.11	137.40	75.67	54.67	-
Diluted weighted shares shares (M)	155.11	137.40	75.67	54.67	-

Annexon Inc-Aktie (ANNX) Insiderhandel

Love DouglasSep 24 '26
PRESIDENT AND CEO
Transaktion
Buy
Kosten
$3.83
#Aktien
26,065
Wert ($)
99,829
#Aktien Gesamt
390,476
WIGGANS THOMAS GAug 13 '26
Former Director
Transaktion
Proposed Sale
Kosten
$5.30
#Aktien
2,000
Wert ($)
10,596
#Aktien Gesamt
0
WIGGANS THOMAS GJul 15 '26
Former Director
Transaktion
Proposed Sale
Kosten
$6.32
#Aktien
2,000
Wert ($)
12,630
#Aktien Gesamt
0
WIGGANS THOMAS GJul 14 '26
Former Director
Transaktion
Proposed Sale
Kosten
$5.61
#Aktien
1,000
Wert ($)
5,605
#Aktien Gesamt
0
Yednock TedJun 11 '26
EVP & CHIEF INNOVATION OFFICER
Transaktion
Option Exercise
Kosten
$1.85
#Aktien
30,646
Wert ($)
56,698
#Aktien Gesamt
184,807
Satter Muneer AMay 28 '26
Director
Transaktion
Buy
Kosten
$5.41
#Aktien
613,497
Wert ($)
3,319,019
#Aktien Gesamt
10,342,134
Carson William H.May 11 '26
Director
Transaktion
Buy
Kosten
$5.78
#Aktien
8,000
Wert ($)
46,240
#Aktien Gesamt
78,405
Carson William H.Apr 10 '26
Director
Transaktion
Buy
Kosten
$6.20
#Aktien
8,000
Wert ($)
49,600
#Aktien Gesamt
70,405
Carson William H.Mar 10 '26
Director
Transaktion
Buy
Kosten
$5.67
#Aktien
8,000
Wert ($)
45,360
#Aktien Gesamt
62,405
Yednock TedMar 02 '26
EVP & CHIEF INNOVATION OFFICER
Transaktion
Sale
Kosten
$5.42
#Aktien
5,566
Wert ($)
30,168
#Aktien Gesamt
154,161

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Love Douglas	PRESIDENT AND CEO	Sep 24 '26	Buy	$3.83	26,065	99,829	390,476
WIGGANS THOMAS G	Former Director	Aug 13 '26	Proposed Sale	$5.30	2,000	10,596	0
WIGGANS THOMAS G	Former Director	Jul 15 '26	Proposed Sale	$6.32	2,000	12,630	0
WIGGANS THOMAS G	Former Director	Jul 14 '26	Proposed Sale	$5.61	1,000	5,605	0
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jun 11 '26	Option Exercise	$1.85	30,646	56,698	184,807
Satter Muneer A	Director	May 28 '26	Buy	$5.41	613,497	3,319,019	10,342,134
Carson William H.	Director	May 11 '26	Buy	$5.78	8,000	46,240	78,405
Carson William H.	Director	Apr 10 '26	Buy	$6.20	8,000	49,600	70,405
Carson William H.	Director	Mar 10 '26	Buy	$5.67	8,000	45,360	62,405
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Mar 02 '26	Sale	$5.42	5,566	30,168	154,161

Annexon Inc Aktie (ANNX) Neueste Nachrichten

Oct 16, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 16, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Oct 16, 2026

Oct 01, 2026

Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance Australia

Oct 01, 2026

Sep 27, 2026

Insider Spends US$100k Buying More Shares In Annexon - simplywall.st

Sep 27, 2026

Sep 25, 2026

After buying shares at a $3.83 average, Annexon (ANNX) CEO Love Douglas holds 390,476 shares. - Stock Titan

Sep 25, 2026

Sep 24, 2026

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting - Investing News Network

Sep 24, 2026

More than 8 million people have an eye disease that can cause blindness. Annexon will present trial findings. - Stock Titan

Sep 24, 2026

Sep 16, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 16, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 16, 2026

Sep 10, 2026

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com Nigeria

Sep 10, 2026

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com South Africa

Sep 10, 2026

ANNX: Vonaprument's phase III trial in GA shows promise for vision preservation and broad market impact - TradingView

Sep 10, 2026

ANNX: Phase III GA study shows strong vision preservation, with high compliance and dual primary endpoints - TradingView

Sep 10, 2026

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com UK

Sep 10, 2026

Sep 09, 2026

ANNX: Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation - TradingView

Sep 09, 2026

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com India

Sep 09, 2026

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com

Sep 09, 2026

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com Canada

Sep 09, 2026

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com UK

Sep 09, 2026

Sep 02, 2026

Annexon to Participate in Upcoming September Investor Conferences - Investing News Network

Sep 02, 2026

Annexon to Participate in Upcoming September Investor Conferences - finance.yahoo.com

Sep 02, 2026

Sep 01, 2026

What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders - Yahoo Finance

Aug 24, 2026

Aug 20, 2026

Annexon (ANNX): Pipeline Momentum Is Building, but Cash Discipline Still Runs the Story - AlphaStreet

Aug 20, 2026

Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current Update - Margin Guidance - vinanet.vn

Aug 20, 2026

Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current Update - One-Time Gain Impact - dars.gov.et

Aug 20, 2026

Aug 19, 2026

Annexon (ANNX) Q2 2026 Earnings Call Transcript - AOL.com

Aug 19, 2026

Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside - TradingView

Aug 19, 2026

Annexon (ANNX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 19, 2026

Aug 18, 2026

Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com

Aug 18, 2026

Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX - MarketBeat

Aug 18, 2026

Aug 17, 2026

Annexon Inc (ANNX) Stock News Today - TradingKey

Aug 17, 2026

Annexon Inc (ANNX) Stock News Today - TradingKey

Aug 17, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Aug 17, 2026

At $5.29, Annexon grants new employees options vesting over four years - Stock Titan

Aug 17, 2026

Annexon (ANNX) Adds Dual Primary Endpoint in Phase 3 Trial, Refl - GuruFocus

Aug 17, 2026

Annexon (ANNX) Earnings Call zu Q2 2026: ARCHER II erweitert, BLA-Einreichung im Zeitplan - TradingKey

Aug 17, 2026

Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track - TradingKey

Aug 17, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com

Aug 17, 2026

What is HC Wainwright's Estimate for Annexon Q3 Earnings? - MarketBeat

Aug 17, 2026

Aug 15, 2026

Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed - Sahm

Aug 15, 2026

Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat

Aug 15, 2026

ANNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Aug 15, 2026

Aug 14, 2026

Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed - webull.com

Aug 14, 2026

Aug 13, 2026

State Street Corp Boosts Annexon Inc (ANNX) Stake by 42% in June Transaction - GuruFocus

Aug 13, 2026

A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27 - Moomoo

Aug 13, 2026

Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise - Stock Titan

Aug 13, 2026

Annexon (ANNX), What Is Behind Its Latest Update? - Yahoo Finance

Aug 13, 2026

Ähnlich wie ANNX

Annexon Inc (ANNX)

Annexon Inc Aktie (ANNX) Unternehmensprofil

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Annexon Inc Aktie (ANNX) Hochstufungen & Herabstufungen

Finanzdaten der Annexon Inc-Aktie (ANNX)

Annexon Inc-Aktie (ANNX) Insiderhandel

Annexon Inc Aktie (ANNX) Neueste Nachrichten

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance Australia

Insider Spends US$100k Buying More Shares In Annexon - simplywall.st

After buying shares at a $3.83 average, Annexon (ANNX) CEO Love Douglas holds 390,476 shares. - Stock Titan

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting - Investing News Network

More than 8 million people have an eye disease that can cause blindness. Annexon will present trial findings. - Stock Titan

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com Nigeria

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com South Africa

ANNX: Vonaprument's phase III trial in GA shows promise for vision preservation and broad market impact - TradingView

ANNX: Phase III GA study shows strong vision preservation, with high compliance and dual primary endpoints - TradingView

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com UK

ANNX: Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation - TradingView

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com India

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com Canada

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com UK

Annexon to Participate in Upcoming September Investor Conferences - Investing News Network

Annexon to Participate in Upcoming September Investor Conferences - finance.yahoo.com

ANNX Maintained by JP Morgan -- Price Target Raised to $14.00 - GuruFocus

ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10 - Moomoo

ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10 - Bitget

What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders - Yahoo Finance

Annexon (ANNX): Pipeline Momentum Is Building, but Cash Discipline Still Runs the Story - AlphaStreet

Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current Update - Margin Guidance - vinanet.vn

Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current Update - One-Time Gain Impact - dars.gov.et

Annexon (ANNX) Q2 2026 Earnings Call Transcript - AOL.com

Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside - TradingView

Annexon (ANNX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com

Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX - MarketBeat

Annexon Inc (ANNX) Stock News Today - TradingKey

Annexon Inc (ANNX) Stock News Today - TradingKey

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

At $5.29, Annexon grants new employees options vesting over four years - Stock Titan

Annexon (ANNX) Adds Dual Primary Endpoint in Phase 3 Trial, Refl - GuruFocus

Annexon (ANNX) Earnings Call zu Q2 2026: ARCHER II erweitert, BLA-Einreichung im Zeitplan - TradingKey

Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track - TradingKey

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com

What is HC Wainwright's Estimate for Annexon Q3 Earnings? - MarketBeat

Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed - Sahm

Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat

ANNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed - webull.com

State Street Corp Boosts Annexon Inc (ANNX) Stake by 42% in June Transaction - GuruFocus

A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27 - Moomoo

Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise - Stock Titan

Annexon (ANNX), What Is Behind Its Latest Update? - Yahoo Finance

Ähnlich wie ANNX